Myelodysplastic Syndrome Market Poised for Growth Through 2036

The clinical landscape is moving rapidly beyond traditional supportive care and hypomethylating agents. Current market leaders like luspatercept, imetelstat, and ivosidenib have set a baseline, but the pipeline is crowded with novel candidates. Companies including Takeda, Orca Bio, and Faron Pharmaceuticals are advancing therapies such as Orca-T, bexmarilimab, and lisaftoclax to address specific patient needs, particularly in transfusion-dependent and relapsed/refractory cases.

Aparna Thakur, project manager at DelveInsight, noted that Rigel Pharmaceuticals is emerging as a significant competitor, leveraging both targeted and immune-modulating assets. This diversification is critical as diagnostic advancements allow for more precise patient stratification. As molecular testing becomes standard, these therapies are increasingly tailored to individual genetic profiles, potentially improving long-term outcomes for patients who previously had limited options.